---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-22-000066"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2022-06-24T23:59:59+00:00"
generated_at: "2026-06-24T23:23:00.203397+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PTAB denies post-grant review of two Compass Pathways patents

## Summary
- Patent Trial & Appeal Board denied institution of post-grant review for US patents 10,947,257 and 10,954,259 on June 22, 2022.
- Freedom to Operate had filed petitions challenging patentability on three grounds: improper subject matter, obviousness, and lack of enablement.
- Decision upholds validity of key patents covering COMPASS's psilocybin-related intellectual property.
- Outcome removes near-term patent invalidation risk for Compass Pathways.

## SEC filing metadata
- accession: 0001816590-22-000066
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2022-06-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659022000066/0001816590-22-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659022000066/cmps-20220622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-22-000066
- JSON: https://secwatch.observer/filing/0001816590-22-000066.json
- Plain text: https://secwatch.observer/filing/0001816590-22-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.